Global Acute Myeloid Leukemia Therapeutics Market 2015-2019

About Acute Myeloid Leukemia
Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor cells. Neoplasms arise from bone marrow, however, it spreads quickly into the blood. In the later stages of the disorder, it spreads to spleen, lymph node, liver, brain, spinal cord and testicles. Clonal expansion of the myeloid blasts and the loss of normal hematopoiesis are the main characteristic of acute myeloid leukemia. The disease affects the elderly people with age of 67 years. Fever, pallor, fatigue and hemorrhages are some of the clinical symptoms of the disease. Smoking, exposure to certain chemicals such as benzene, exposure to radiations, cancer patients, who are treated with chemotherapy, blood disorder or genetic mutations are some of the risk factors for the development of  acute myeloid leukemia in patients.
TechNavio's analysts forecast the Global Acute Myeloid Leukemia Therapeutics market to grow at a CAGR of 19.75 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Acute Myeloid Leukemia Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label and branded therapies used for treatment.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Acute Myeloid Leukemia Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, Global Acute Myeloid Leukemia Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC regions and the EMEA regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA   
    
Key Vendors
• Bristol Myers Squibb
• Celgene
• Johnson & Johnson
• Pfizer

Other Prominent Vendors
 • Abbott
• Ambit BioSciences
• Amgen
• Astex Pharmaceuticals
• AstraZeneca
• Baxter Healthcare
• Bayer
• Boehringer Ingelheim
• Celator Pharmaceuticals
• Chroma Therapeutics
• Chugai Pharmaceutical
• CTI Biopharma
• Cyclacel Pharmaceuticals
• Eisai
• F. Hoffmann-La Roche
• Immune Pharmaceuticals
• Innate Pharma
• Kanisa Pharmaceuticals
• Meda
• Merck Sharp & Dohme
• Midas Pharmaceuticals
• Neovii Biotech
• Nippon Shinyaku
• Novo Nordisk
• Sanofi
• Sunesis Pharmaceuticals
• Teva Pharmaceutical
• Tolero Pharmaceuticals

Market Driver
• Unmet Needs in the Market
• For a full, detailed list, view our report

Market Challenge
• Expensive Treatment
• For a full, detailed list, view our report

Market Trend
• Expected Entry of Novel Therapies
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.